Arzneimittelwerk Dresden Gmbh

Asta Medica, Aktiengesellschaft

Reni Bartsch

Angelika Rostock

Chris Rundfeldt

Christine Tober

Dieter Lohmann

Hildegard Poppe

Klaus Unverferth

Natalja V Kaverina

Valentin V Lyskovzev

Hans-Joachim Lankau

Rita Dost

Wolfgang Sauer

Helmut Wunderlich

Thomas Arnold

Anna N Grizenko

Aleksandr P Skoldinov

Andreas Stark

Gottfried Faust

Hans-Joachim Jansch

Alexandr P Skoldinov

Vladimir G Granik

Christine Siegemund

Lothar Zenker

Carla Ruger

Arkadij M Lichoserstov

Yekaterina K Grigoryeva

Yekaterina A Talmachova

Gennadi G Chichkanov

Alwina W Stawrowskaya

Lothar Zenkar

Ekaterina K Grigoreva

Abgelika Rostock

Sofia Grizik

Vladimir Granik

The invention relates to 1,5-dihydropyrrol-2-ones of Formula 1 which contain an aryl radical in the 1-position and a secondary amine radical in the 4-position, to a process for making and for a process to treat various forms of epilepsies and of states of anxiety and tension.

4-amino-1-aryl-1,5-dihydropyrrol-2-ones and process for making

The invention relates to the use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene of formula I ##STR1## or its pharmaceutically utilizable salts, for the prophylaxis and treatment of neuropathic pain.

Use of retigabine for the treatment of neuropathic pain

Antiepileptic compounds of the formula ##STR1## wherein X is hydrogen, a C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl, trifluoromethoxy or halogen residue, A is an amino, C.sub.1-4 alkylamino, C.sub.1-4 dialkylamino, morpholino, piperidino or pyrrolidino residue, and n is a cardinal number from 0 to 5, and process for preparing the foregoing compounds and for their use as anticonvulsives.

4-amino-1-arylpyridin-2-ones and process for making

A process for the treatment of anxiety and tension, which comprises administering to a patient in need therefor an anxiolytically effective amount of a compound of the formula ##STR1## wherein X is hydrogen, a C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl residue, or halogen; R.sup.1 and R.sup.2 are independently of each other a C.sub.1-4 alkyl, cycloalkyl, C.sub.2-4 hydroxyalkyl, or heteroalkyl residue, or R.sup.1 and R.sup.2 together form a C.sub.2-6 alkylene residue in which one --CH.sub.2 -- group can be replaced by oxygen, nitrogen or sulfur; n is 0 or 1, and m is 0 or a cardinal number from 1-5, or a pharmaceutically acceptable salt of the compound.

For a process for treatment of anxiety and tension

The use of the compound I ##STR1## or its pharmaceutically utilizable salts for the propylaxis and treatment of the squelae of chronic reduced cerebral blood supply, in particular of stroke, and for the treatment of nuerodegenerative disorders is claimed.

Use of 2-4-amino-4-(4-fluorobenzylamino) (-1-ethoxy-carbonylaminobenzene

The use of the compound I ##STR1## or its pharmaceutically utilizable salts for the propylaxis and treatment of the sequel of chronic reduced cerebral blood supply, in particular of stroke, and for the treatment of neurodegenerative disorders is claimed.

Use of 4-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for

5-(w-Aminoacyl)-5,10-dihydro-11H-dibenzo(b,e)(1,4)-diazepine-11-ones, and their preparation are disclosed for treatment of antiarrhythmia and as an anticholinergic drug.

5-(1-aminoacyl)-5,10-dihydro-11H-dibenzo[b,e](1,4)diazepin-11-ones

New 3-carbalkoxyamino-5-(alpha-aminopropionyl)-5H-dibenz[b,f]azepines of formula I and their pharmaceutically acceptable salts were found to be suitable actives for the treatment of cardiac arrhythmia. Previously unknown 3-carbalkoxyamino-5-(alpha-halogenpropionyl)-5H-dibenz[b,f]azepines are obtained from 3-carbalkoxyamino-5H-dibenz[b,f]azepines by reaction with alpha-halogenpropionyl halides. Through their reaction with ammonia, primary amines or secondary amines, the new 3-carbalkoxyamino-5-(alpha-aminopropionyl)-5H-dibenz[b,f]azepines are obtained, which can be optionally converted into their pharmaceutically acceptable acid addition salts.

3-carbalkoxyamino-5-(alpha-aminopropionyl)-5H-dibenz[b,f]azepines and

The substituted 5-(phenoxyalkanoylamino)-uracil compounds have the following formula I: ##STR1## wherein R.sub.1 and R.sub.2 are each independently hydrogen; a branched or linear alkyl group having 1 to 6 carbon atoms; a branched or straight chain alkenyl or alkynyl group having 1 to 6 carbons atoms; a cycloalkyl group having from 3 to 7 carbon atoms or a cycloalkylmethyl group having a cycloalkyl residue of 3 to 7 carbon atoms; or a phenylalkyl group having an alkyl residue having from 1 to 3 carbon atoms and a phenyl residue, the phenyl residue being unsubstituted or having a halogen, methoxy, methyl or trifluoromethyl substituent; R.sub.3 is a hydrogen, methyl or amino groups; R.sub.4 is halogen, methoxy or methyl groups, and n is 1 or 2. Pharmaceutical compositions for treating cerebrovascular, neuronal-degenerative and senility-induced disorders associated with learning, memory and cognitive dysfunctions are described which contain a therapeutically effective amount of the substituted 5-(phenoxyalkanoylamino)-uracil in a pharmaceutically acceptable carrier.

Substituted 5-(phenoxyalkanoylamino)-uracil compounds, methods for

New 3-carbalkoxyamino-5-aminoacyl-5H-dibenz[b,f]azepines and their pharmaceutically acceptable acid addition salts, and methods for their synthesis are described. These compounds are useful as antiarrhythmic agents in the treatment of heart disorders. The new compounds are made by reacting a 3-carbalkoxyamino-5-halogenacyl-5H-dibenz[b,f]azepines with an amine to form the desired target product, which can be optionally converted into its pharmaceutically acceptable acid addition salt.

3-carbalkoxyamino-5-aminoacyl-5H-dibenz[b,f]azepines, and methods for

Growing community of inventors

Dresden, Germany

Reni Bartsch